Variant position: 850 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 944 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human LFVALSPQGTAQGELFLDDG HTFNYQTRQEFLLRRFSFSGN
Mouse LFVALSPQGTAQGELFLDDG HTFNYQTRHEFLLRRFSFSGS
Pig LFVALSPQGTAQGELFLDDG HTFNYQTGHEFLLRRFSFSGN
Slime mold IRIALDSSKSAQGQLYIDDE HSFDYKKG-KFLYRQFTFKDN
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
29 – 944 Neutral alpha-glucosidase AB
53 – 944 Missing. In isoform 3.
Sequence and analysis of the endoplasmic reticulum protein glucosidase II.
Stuerzenhofecker B.; Nguyenvan P.; Soeling H.D.;
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1); VARIANT TYR-850;
Prediction of the coding sequences of unidentified human genes. III. The coding sequences of 40 new genes (KIAA0081-KIAA0120) deduced by analysis of cDNA clones from human cell line KG-1.
Nagase T.; Miyajima N.; Tanaka A.; Sazuka T.; Seki N.; Sato S.; Tabata S.; Ishikawa K.; Kawarabayasi Y.; Kotani H.; Nomura N.;
DNA Res. 2:37-43(1995)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2-944 (ISOFORM 1); VARIANT TYR-850;
Isolated polycystic liver disease genes define effectors of polycystin-1 function.
Besse W.; Dong K.; Choi J.; Punia S.; Fedeles S.V.; Choi M.; Gallagher A.R.; Huang E.B.; Gulati A.; Knight J.; Mane S.; Tahvanainen E.; Tahvanainen P.; Sanna-Cherchi S.; Lifton R.P.; Watnick T.; Pei Y.P.; Torres V.E.; Somlo S.;
J. Clin. Invest. 127:1772-1785(2017)
Cited for: VARIANTS ASN-785; TYR-850 AND 918-GLN--ARG-944 DEL; CHARACTERIZATION OF VARIANTS ASN-785 AND TYR-850;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.